Seeb

This research aims to evaluate the use of luspatercept treatment in adults with transfusion-dependent beta-Thalassemia in the Middle East. The study focuses on people who require regular blood transfusions due to this genetic blood disorder. The goal is to understand how luspatercept, a drug given according to its official guidelines, affects these patients in real-world clinical settings. Participants receive luspatercept following the product's approved label. The study includes adults who have started this treatment within the last 12 months and are continuing therapy. The study is observational, meaning it collects information on patients receiving luspatercept as part of their usual care without altering their treatment. During the study, researchers monitor changes in the participants' need for blood transfusions and their hemoglobin levels before transfusions, from the start of treatment up to week 144. Participants provide informed consent for their medical data to be collected and analyzed. The study observes safety and effectiveness over this extended period to better understand luspatercept's impact on transfusion-dependent beta-Thalassemia.